论文部分内容阅读
目的探讨巴曲酶和低分子肝素(LMWH)治疗急性脑梗死的疗效。方法连续积累2002-01~2004-03广东佛山市顺德桂洲医院150例急性脑梗死住院患者,随机分为巴曲酶组(42例)、低分子肝素组(48例)和对照组(60例),均在发病后6~72h内给药,治疗前后对神经功能缺损程度进行评价,比较巴曲酶与低分子肝素治疗急性脑梗死的疗效。结果巴曲酶组治愈率显著高于低分子肝素组(P<0.05),治疗后巴曲酶组患者的神经功能缺损程度的恢复也显著优于低分子肝素组(P<0.05)。结论巴曲酶治疗急性脑梗死疗效优于低分子肝素。
Objective To investigate the curative effect of batroxobin and low molecular weight heparin (LMWH) on acute cerebral infarction. Methods A total of 150 hospitalized acute cerebral infarction patients were randomly divided into batroxobin group (42 cases), low molecular weight heparin group (48 cases) and control group (60 cases) Cases) were given within 6 to 72 hours after onset. The degree of neurological impairment was evaluated before and after treatment. The efficacy of batroxobin and LMWH in the treatment of acute cerebral infarction was compared. Results The cure rate of Batroxobin group was significantly higher than that of low molecular weight heparin group (P <0.05). The recovery of neurological deficit in Batroxobin group was also significantly better than that of low molecular weight heparin group (P <0.05). Conclusion Batroxobin is superior to low molecular weight heparin in the treatment of acute cerebral infarction.